Do not miss! clustersrl.it/res-wfsc?fbcli…

New #JITC article: Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties bit.ly/3pW3yFk Sripad Ram

Mucosal melanomas: molecular profile and therapy. What physicians need to know!!

👉 Check out the ESMO - Eur. Oncology Practicing Oncologists Working Group's new series of Spotlight presentations featuring highlights from #ESMO21 oncologypro.esmo.org/meeting-resour…

On behalf of my colleagues, so excited to bring a new and safer immune checkpoint inhibitor combination to our patients with advanced melanoma, Relatlimab (anti-LAG3) with nivolumab improves PFS, minor increase in toxicity, new frontiers for #Immunotherapy nejm.org/doi/full/10.10…

Just published! We proudly present "Hallmarks of Cancer: New Dimensions" by Douglas Hanahan, the third update to the seminal series. bit.ly/3GkSqZK Ludwig Cancer

#ESMOPreceptorship on Molecular #CancerBiology for Practising Oncologists & #Cancer Treatment De-escalation 2022: Multidisciplinary management, standards of care & future perspectives ow.ly/pgJv50HQFsZ Bennouna Jaafar Birute Brasiuniene MD PhD @PietDirix @G_LipositsMD Lazar Popovic

Soft Tissue #Sarcomas Webinar ⏰ 29/3, 18:30 CEST Registration open for this live discussion of a real-world case. Live viewers: certificate of attendance & 1 ESMO-MORA point Full info 🔗 ow.ly/YIT950ImoNY Alice Indini Silvia Stacchiotti Pawel Sobczuk Jean-Yves Blay #scmsm

Our study on #mucosal #melanoma is now online in Annals of Oncology - Although retrospective, this study represents the largest report to date analyzing the efficacy of ICIs in this rare cancer that carries a poor prognosis. Here are some key points:

Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. pubmed.ncbi.nlm.nih.gov/35752398/

Calling all practising oncologists 📢 Take the ESMO Practising Oncologists Working Group survey so we can better understand your practice needs & opinions on current products. ow.ly/FS3650KMUi7 Birute Brasiuniene MD PhD Meredith GTrinidad, MD Lazar Popovic Bennouna Jaafar @G_LipositsMD

Great job from the Practising Oncologist Working Group! Very useful!!!!

Alexios Matikas, OncologyPRO Working Group Member & ESMO #YoungOncologist Committee Member, on why OncologyPRO is an essential tool to help oncologists in their #dailypractice, thanks to its accessibility, ease of use, and content depth. ow.ly/pmwU50M9esW #oncology

Great job, #Iampractisingoncologist! We r the @esmo_eur_oncology commitee involved in feeling the gap between research and daily clinical practice. If you have a full 8-hours clinic and look4a way to be updated on what’s going on in the oncology field, welcome on board!

What is the real benefit of adjuvant therapy in stage II and III melanoma? A group of experts critically reviewed the results so far reported. A must read article to guide therapeutic choices in a debated setting! #IAmPractisingOncologist #melanoma ejcancer.com/article/S0959-…